BRIDGEWATER, N.J. — Amneal Pharmaceuticals LLC has formed Amneal Biosciences, a new business unit.
Amneal said Tuesday that the new subsidiary will focus exclusively on the commercialization of high-barrier-to-entry generic drugs and specialty pharmaceuticals — such as injectables, oncologics and biosimilars — health care providers worldwide.
“Having a dedicated company focused on the unique needs and logistics of this market segment allows Amneal to guarantee the same level of quality and service to healthcare institutions and professionals that we deliver to our existing retail customers,” stated Amneal chairman and co-chief executive officer Chirag Patel. “Amneal has a robust pipeline of both small-molecule injectable generics as well as biosimilars, and we expect to bring the first of these to market in early 2016. Our experienced Amneal Biosciences team provides the high degree of expertise these specialty products require.”
In announcing the creation of Amneal Biosciences, Amneal said the new unit will be led by Charles Lucarelli, who will serve as president. The pharmacy veteran joined Amneal in March after a 37-year career at Memorial Sloan Kettering Cancer Center, including 25 years as director of pharmacy.
In that position, Lucarelli took direct responsibility for the pharmacy department and its regional sites and was accountable for inpatient/outpatient pharmaceutical services, clinical services, and hospitalwide investigational drug and research services. He also was a co-investigator on numerous drug studies at Memorial Sloan Kettering and is an internationally known speaker.
“It is an honor to serve as president of Amneal Biosciences and lead this talented group of professionals at such a pivotal time in our company’s evolution,” Lucarelli commented. “Our robust product pipeline will bring the Amneal legacy of quality and customer service to a segment in need of therapeutic affordability and reliable supply.”